305 related articles for article (PubMed ID: 16820210)
1. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics.
Moore ML; Peebles RS
Pharmacol Ther; 2006 Nov; 112(2):405-24. PubMed ID: 16820210
[TBL] [Abstract][Full Text] [Related]
2. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
3. Identifying targets in the hunt for effective respiratory syncytial virus interventions.
Tayyari F; Hegele RG
Expert Rev Respir Med; 2012 Apr; 6(2):215-22. PubMed ID: 22455493
[TBL] [Abstract][Full Text] [Related]
4. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
[TBL] [Abstract][Full Text] [Related]
5. Regulation of airway eosinophil and neutrophil infiltration by alpha-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease.
Benoit AC; Huang Y; Maneewatchararangsri S; Tapchaisri P; Anderson R
Vaccine; 2007 Nov; 25(45):7754-62. PubMed ID: 17920164
[TBL] [Abstract][Full Text] [Related]
6. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
Johnson TR; Graham BS
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
[TBL] [Abstract][Full Text] [Related]
7. Contribution of neuroimmune mechanisms to airway inflammation and remodeling during and after respiratory syncytial virus infection.
Piedimonte G
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S66-74; discussion S74-5. PubMed ID: 12671455
[TBL] [Abstract][Full Text] [Related]
8. Immunization strategies for the prevention of pneumovirus infections.
Bennett N; Ellis J; Bonville C; Rosenberg H; Domachowske J
Expert Rev Vaccines; 2007 Apr; 6(2):169-82. PubMed ID: 17408367
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.
Peebles RS; Sheller JR; Collins RD; Jarzecka K; Mitchell DB; Graham BS
J Infect Dis; 2000 Sep; 182(3):671-7. PubMed ID: 10950758
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus persistence: evidence in the mouse model.
Mejías A; Chávez-Bueno S; Gómez AM; Somers C; Estripeaut D; Torres JP; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S60-2. PubMed ID: 18820580
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases.
Welliver TP; Reed JL; Welliver RC
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S92-6. PubMed ID: 18820587
[TBL] [Abstract][Full Text] [Related]
13. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
14. Advances in respiratory syncytial virus vaccine development.
Kneyber MC; Kimpen JL
Curr Opin Investig Drugs; 2004 Feb; 5(2):163-70. PubMed ID: 15043390
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner?
Hussell T; Openshaw P
Curr Opin Microbiol; 1999 Aug; 2(4):410-4. PubMed ID: 10458984
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model.
Ponnuraj EM; Springer J; Hayward AR; Wilson H; Simoes EA
J Infect Dis; 2003 Apr; 187(8):1257-63. PubMed ID: 12696005
[TBL] [Abstract][Full Text] [Related]
17. [Respiratory syncytial virus: as an etiological agent of respiratory tract infection in children and adults].
Belino-Studzińska P; Pancer K
Przegl Epidemiol; 2008; 62(4):767-75. PubMed ID: 19209739
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease.
Sikkel MB; Quint JK; Mallia P; Wedzicha JA; Johnston SL
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S63-70. PubMed ID: 18820581
[TBL] [Abstract][Full Text] [Related]
19. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
Huang Y; Cyr SL; Burt DS; Anderson R
J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
[TBL] [Abstract][Full Text] [Related]
20. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
